Loading
Pediatrix Medical Group, Inc. Stock: price and insider trades · United States
Pediatrix Medical Group, Inc.: what insiders have been doing
Pediatrix Medical Group, Inc., classified in the Healthcare & Pharma sector, is a listed company based in Sunrise, United States, founded in 1979. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 22 filings came from 15 insiders.
The flow runs one way only: 4 sales worth €1.6M, from 4 insiders, and no purchase. Biggest ticket of the year: €730k, sold by Weis Shirley A and made public on 14 May 2026 (0.040% of market cap).
With 22 filings in twelve months, the company is in line with the median of 22 filings across the 5,458 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed no purchases and 29 sales. The 10-K for the year ended 31 December 2025 shows 1.91 bn USD of revenue and 165.4 m USD of net income.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
131
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€13M
29 ops. · all time
Who traded when
BuySaleMark S. Ordan2 sales
Laura A. Linynsky1 sale
Mary Ann E. Moore1 sale
Michael A. Rucker1 sale
Shirley A. Weis1 sale
Analyst consensus: bullish or bearish?
Analysts rate Pediatrix Medical Group, Inc. Hold (neutral), based on 6 analysts. Average price target: US$26.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 5,369 of 24,148 companies
65.6
score / 100
Value73
Quality59
FCF yld11%
Earn yld7.5%
EV/EBITDA10.3x
ROE20%
Gross mgn26%
Net mgn8.6%
Debt/EBITDA2.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$27.06
Analyst consensus
6 analystsHold
US$21.00Target US$26.33(-3%)US$28.00
Income statement
RevenueUS$1.9B
Gross profitUS$493.7M26% margin
EBITDAUS$274.2M14% margin
Net incomeUS$165.4M9.0% margin
Valuation
PER (trailing)12.9x
PER (forward)11.1x
P/Book2.4x
Beta0.61
Balance sheet & cash
Market capUS$2.2B
Total debtUS$634.6M
Free Cash FlowUS$252.6M
Debt / Equity70%
Profitability & ownership
ROE20.4%
ROA7.1%
% insiders2.0%
% institutions107.2%
Last declaration on 14 September 2026
Declarations131 total
9,260 shares@ US$26.60530.012% mcap30.2% of flowCommonSEC144:0001628280-26-061929
21,335 shares@ US$26.83950.027% mcap69.8% of flowCommonSEC144:0001628280-26-061930
6,000 shares@ US$26.820.0075% mcap34.0% of flowCommon StockSEC:0001193125-26-390731:0
6,000 shares@ US$26.78930.0075% mcap100.0% of flowCommonSEC144:0001628280-26-061367
18,500 shares@ US$26.620.023% mcap97.5% of flowCommon StockSEC:0001193125-26-355656:0
18,500 shares@ US$26.58750.023% mcap100.0% of flowCommonSEC144:0001628280-26-057186
472 shares@ US$26.500.0006% mcap2.7% of flowCommon StockSEC:0001193125-26-352527:0
472 shares@ US$26.500.0006% mcap100.0% of flowCommon StockSEC:0001193125-26-352534:0
472 shares@ US$26.500.0006% mcap100.0% of flowCommon StockSEC:0001193125-26-352528:0
472 shares@ US$26.500.0006% mcap100.0% of flowCommon StockSEC:0001193125-26-352522:0
472 shares@ US$26.500.0006% mcap2.5% of flowCommon StockSEC:0001193125-26-352524:0
472 shares@ US$26.500.0006% mcap100.0% of flowCommon StockSEC:0001193125-26-352531:0
472 shares@ US$26.500.0006% mcap1.1% of flowCommon StockSEC:0001193125-26-352532:0
472 shares@ US$26.500.0006% mcap5.0% of flowCommon StockSEC:0001193125-26-352526:0
20,036 sharesCommon StockSEC:0001193125-26-281304:0
11,427 shares0Common StockSEC:0001193125-26-224279:0
36,028 shares@ US$23.750.040% mcap75.5% of flowCommon StockSEC:0001193125-26-224280:0
3,676 shares@ US$19.8553.9% of flowCommon StockSEC:0001193125-26-088620:0
39,925 shares0Common StockSEC:0001193125-26-088621:0
23,000 shares@ US$22.4114.4% of flowCommon StockSEC:0001193125-25-322897:0
10,478 shares@ US$23.0095.0% of flowCommon StockSEC:0001193125-25-288277:0
10,000 shares@ US$21.6546.2% of flowCommon StockSEC:0001193125-25-274502:0
54,021 shares0Common StockSEC:0000950170-25-110715:0
9,737 shares0Common StockSEC:0000950170-25-103196:0
81,346 shares0Common StockSEC:0000950170-25-103206:0
25 of 131 declarations
About Pediatrix Medical Group, Inc.
Pediatrix Medical Group, Inc. is a U.S.-listed healthcare services company trading on the NYSE under ticker MD. The company is based in Sunrise, Florida, in the United States. Its operating history dates back to 1979, and over time it built a national reputation as a physician-led specialist focused on women, newborns and children. In 2022, the company formally renamed itself from Mednax to Pediatrix Medical Group, a brand consolidation intended to create a clearer identity across its affiliated practices and improve recognition among hospitals, clinicians and patients.
From a business perspective, Pediatrix is now centered on high-acuity medical services, with core capabilities in neonatology, maternal-fetal medicine and other pediatric subspecialties. The group works through specialized physician teams and contractual arrangements with hospitals and other healthcare facilities, allowing it to deliver both clinical expertise and operational support. Its value proposition is closely tied to quality of care, hospital partnership, cost containment and risk mitigation.
Read moreShow less
The company historically maintained a broad network of affiliated practices across the country. However, its portfolio has been deliberately reshaped in recent periods. According to its 2025 annual report, Pediatrix exited almost all of its affiliated office-based practices in 2024, except for maternal-fetal medicine, and also exited its primary and urgent care service line. This is an important strategic signal: management has been narrowing the business toward more specialized and differentiated service lines rather than trying to operate a broader primary-care platform.
In competitive terms, Pediatrix positions itself as a trusted hospital solutions partner with strong clinical depth in maternity, neonatal and pediatric care. Its competitive edge lies in specialty expertise, embedded relationships with hospitals, and the ability to support care quality while helping clients manage staffing, operations and clinical outcomes. The company also emphasizes advanced clinical tools, quality initiatives, training and data-driven processes to support performance.
Geographically, Pediatrix is primarily a United States healthcare platform, operating through a nationwide network of physician practices and hospital-based programs. Recent highlights include the 2022 name change, the 2024 portfolio reset, and continued public-facing messaging in 2025 and 2026 around its hospital solutions and pediatric specialty care platform. For investors, Pediatrix is best viewed as a U.S. specialty healthcare operator focused on clinical specialization, operational discipline and a more streamlined business mix, with the NYSE listing adding visibility for international equity market participants.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
